Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2020

View Archived Issues

TXNIP inhibition nixes T2D

Supportive preclinical reported for PTX-COVID19-B vaccine candidate

First-in-human data presented for NTRX-07

Daiichi Sankyo patents new SIRT6 activators

Merck & Co. synthesizes HDAC inhibitors

Chinese researchers identify LPAR1 antagonists

Innate Tumor Immunity discloses NLRP3 agonists

New adenosine A2A receptor antagonists discovered by Nuvation Bio

Boehringer Ingelheim initiates first-in-human study of BI-764532

Structure-guided analysis unveils the mechanism of action of a dengue virus 2-specific inhibitor

SASS6 is involved in the proliferation of esophageal cancer and may be a novel therapeutic target

AstraZeneca is enrolling participants in phase I study of MEDI-8367

First patient enrolled in phase IIb/III study of ifenprodil for treatment of COVID-19

Six-month follow-up data announced from phase I study of INXN-4001

Anti-podocalyxin [225Ac]PODO-447 shows promise as immunotherapeutic for treating solid tumors

Dicerna provides data updates from clinical and preclinical developments

Topline data presented from phase III CARE-PWS study of LV-101

Phase II/III study of opaganib in patients with COVID-19 receives approval in Mexico

FDA clears IND for phase II study of TNX-102 SL

First patient dosed in a phase Ib/II study FGF-401 plus pembrolizumab

Study links mitochondrial DNA to abscopal response

Roche gives update on phase III IMpassion131 study of Tecentriq

GlycoNex initiates phase I study of GNX-102

First-in-human study of DC immunotherapy in patients with pancreatic adenocarcinoma

EC approves Xolair as treatment of severe chronic rhinosinusitis with nasal polyps

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...